Related Experiment Video

Updated: Aug 20, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design

Nina Singh1

  • 1Veterans Affairs Medical Center and University of Pittsburgh, Thomas E. Starzl Transplantation Institute, Pittsburgh, PA 15240, USA. nis5+@pitt.edu

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|November 17, 2004
PubMed
Abstract

Insights

Designing clinical trials for antifungal prophylaxis in organ transplant recipients requires careful consideration of patient subgroups and drug safety. Evolving epidemiology necessitates updated strategies for invasive mycoses prevention in this vulnerable population.

Area of Science:

  • Infectious Diseases
  • Clinical Trial Design
  • Transplantation Medicine

Background:

  • Key challenges exist in designing clinical trials for antifungal prophylaxis in organ transplant recipients.
  • The epidemiology and risk factors for invasive fungal infections (IFIs) in this population are evolving.

Purpose of the Study:

  • To inform optimal clinical trial design for antifungal prophylaxis in organ transplant recipients.
  • To identify appropriate patient subgroups, endpoints, and drug candidates for prophylaxis trials.

Main Methods:

  • Review of existing and emerging data on epidemiology and risk factors for IFIs in organ transplant recipients.
  • Consideration of drug safety, tolerability, and potential interactions with immunosuppressive agents.

Main Results:

  • Epidemiological shifts in IFIs warrant reconsideration of target patient subsets and fungal pathogens for prophylaxis trials.
  • Safety, tolerability, and outcome stratification by illness severity are critical endpoints.
  • Documenting a beneficial effect of prophylaxis on outcomes remains challenging in organ transplant recipients.

Conclusions:

  • Clinical trial design must address patient selection for maximal benefit.
  • Tolerability and drug interactions of antifungal agents are crucial considerations in organ transplant recipients.

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...